QPT.V : Summary for QUEST PHARMATECH INC. - Yahoo Finance

U.S. Markets closed

Quest PharmaTech Inc. (QPT.V)


TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.11-0.01 (-4.35%)
At close: 11:36AM EST
People also watch
MIR.VCZO.VPYT.VMBI.VDMA.V
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.12
Open0.12
Bid0.11 x
Ask0.12 x
Day's Range0.11 - 0.12
52 Week Range0.04 - 0.19
Volume220,100
Avg. Volume222,478
Market Cap16.5M
Beta2.13
PE Ratio (TTM)-2.68
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group11 days ago

    Quest PharmaTech Announces Results from its 2017 AGM

    Quest PharmaTech Announces Results from its 2017 AGM

  • CNW Group3 months ago

    OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

    OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

  • PR Newswire3 months ago

    OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

    EDMONTON, Dec. 7, 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced that it has entered into an Antibody Manufacturing Development Program with Cytovance Biologics (Oklahoma City, OK, USA) for its oregovomab antibody product. Supported by recent positive interim clinical results from its Phase IIb clinical study in ovarian cancer patients, OncoQuest has engaged Cytovance to establish a reliable and stable supply of its oregovomab antibody drug product to support anticipated registration clinical studies and future commercial needs. Oregovomab is currently being tested with standard chemotherapy combination in the front line setting of ovarian cancer treatment.